Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 16/20 | 0.43 |
| ▸ | CSF1R | P07333 | 14/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.38 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.38 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29894138 | 1.00 | EGFR (0.43) | EGFRCSF1RHTR2AHTR2CFGFR4 | |
| SCHEMBL5769575 | 0.88 | EGFR (0.43) | EGFRCSF1RFGFR4FGFR1MAPK14 | |
| SCHEMBL5769117 | 0.86 | EGFR (0.41) | EGFRCSF1RFGFR4MAPK14 | |
| SCHEMBL5767953 | 0.86 | EGFR (0.41) | EGFRCSF1RFGFR4FGFR1MAPK14 | |
| SCHEMBL16573715 | 0.84 | FGFR4 (0.50) | EGFRCSF1RFGFR4FGFR1MAPK14 | |
| SCHEMBL5768549 | 0.84 | EGFR (0.43) | EGFRCSF1RFGFR4MAPK14 | |
| SCHEMBL5768657 | 0.82 | EGFR (0.41) | EGFRCSF1RFGFR4FGFR1FGFR2 | |
| SCHEMBL29894305 | 0.82 | MAPK14 (0.61) | EGFRCSF1RFGFR4MAPK14 | |
| SCHEMBL5231399 | 0.82 | MAPK14 (0.61) | EGFRCSF1RFGFR4MAPK14 | |
| SCHEMBL5231396 | 0.82 | MAPK14 (0.61) | EGFRCSF1RFGFR4MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021084266-A1 | BICYCLIC NITROGEN CONTAINING HETEROCYCLES AS INHIBITORS OF SALT-INUCED KINASE SIK2 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-05-06 | — | — | WO | claimed |
| EP-1226144-B1 | ALKYLAMINO SUBSTITUTED BICYCLIC NITROGEN HETEROCYCLES AS INHIBITORS OF P38 PROTEIN KINASE | HOFFMANN LA ROCHE (CH) | 2006-12-27 | — | — | EP | claimed |
| EP-1226144-A1 | ALKYLAMINO SUBSTITUTED BICYCLIC NITROGEN HETEROCYCLES AS INHIBITORS OF P38 PROTEIN KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2002-07-31 | — | — | EP | claimed |
| WO-2001029041-A1 | ALKYLAMINO SUBSTITUTED BICYCLIC NITROGEN HETEROCYCLES AS INHIBITORS OF P38 PROTEIN KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2001-04-26 | — | — | WO | claimed |
| US-12509457-B2 | Bicyclic nitrogen containing heterocycles as inhibitors of salt-induced kinase SIK2 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2025-12-30 | — | — | US | disclosed |
| US-20230014742-A1 | BICYCLIC NITROGEN CONTAINING HETEROCYCLES AS INHIBITORS OF SALT-INDUCED KINASE SIK2 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-01-19 | — | — | US | disclosed |
| WO-2021084266-A1 | BICYCLIC NITROGEN CONTAINING HETEROCYCLES AS INHIBITORS OF SALT-INUCED KINASE SIK2 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-05-06 | — | — | WO | disclosed |
| EP-1226144-B1 | ALKYLAMINO SUBSTITUTED BICYCLIC NITROGEN HETEROCYCLES AS INHIBITORS OF P38 PROTEIN KINASE | HOFFMANN LA ROCHE (CH) | 2006-12-27 | — | — | EP | disclosed |
| US-6642241-B1 | Alkylamino- substituted dihydropyrimido-(4,5-d)pyrimidinone derivatives, inhibitors of p38, | SYNTEX (U.S.A.) LLC | 2003-11-04 | — | — | US | disclosed |
| EP-1226144-A1 | ALKYLAMINO SUBSTITUTED BICYCLIC NITROGEN HETEROCYCLES AS INHIBITORS OF P38 PROTEIN KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2002-07-31 | — | — | EP | disclosed |
| WO-2001029041-A1 | ALKYLAMINO SUBSTITUTED BICYCLIC NITROGEN HETEROCYCLES AS INHIBITORS OF P38 PROTEIN KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2001-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230014742-A1 | BICYCLIC NITROGEN CONTAINING HETEROCYCLES AS INHIBITORS OF SALT-INDUCED KINASE SIK2 | SIK2, SIK1, SIK3 | EGFR 1693/4885CSF1R 1398/4885HTR2A 2642/4885 |
| US-12509457-B2 | Bicyclic nitrogen containing heterocycles as inhibitors of salt-induced kinase SIK2 | SIK2, SIK1, SIK3 | EGFR 1167/4885CSF1R 1324/4885HTR2A 1432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.